You are here

FDA Accepts New Drug Application of Abraxane for the Treatment of Metastatic Breast Cancer

SCHAUMBURG, Ill., May 10 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. (APP) (NASDAQ:APPX) and American BioScience, Inc. (ABI) today announced that the New Drug Application (NDA) for ABRAXANE(TM) has been accepted for filing with standard review by the U.S. Food and Drug Administration (FDA), indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.

"I am very proud of the tremendous effort by the entire development team in accomplishing this successful filing of an electronic NDA. FDA's acceptance of this NDA filing moves us one step closer to providing a potential new treatment for metastatic breast cancer patients," said Patrick Soon-Shiong, M.D., Chairman, President and Chief Executive Officer of American Pharmaceutical Partners. "By meeting this important milestone our clinical development plan for ABRAXANE in breast cancer remains on track. With this acceptance we are now aggressively expanding our clinical development program to pursue indications in other malignancies such as non-small cell lung cancer and ovarian cancer, as well as combination therapies of ABRAXANE with other chemotherapeutic agents."

The filing of the NDA is based primarily upon the pivotal randomized controlled Phase III trial that compared the safety and efficacy of 260 mg/m2 of ABRAXANE to 175 mg/m2 of TAXOL(R) administered every three weeks in 460 patients with metastatic breast cancer. The Phase III trial demonstrated that ABRAXANE resulted in an almost doubling of the response rate and a prolongation of time to tumor progression in first and second line patients with metastatic breast cancer.

ABI and APP are strategic partners in the development, manufacture and marketing of ABRAXANE. ABI is responsible for the clinical development and registration of ABRAXANE. APP has licensed the exclusive North American manufacturing and marketing rights for ABRAXANE.

About Breast Cancer
According to the American Cancer Society (ACS), while early detection efforts have decreased mortality rates, in 2004 an estimated 215,990 women are expected to be diagnosed with breast cancer that had already spread. Breast cancer is still the leading overall cause of death in women between the ages of 20 and 59, with 40,110 deaths estimated in 2004. One of every three cancers diagnosed in the United States is breast cancer; excluding skin cancer, it's the most common cancer among women.

Source: American Pharmaceutical Partners, Inc. and American BioScience, Inc.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time